NCT01091142 - Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

September 30, 2010

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

NP001

Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)

DRUG

Placebo

Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo

Trial Locations (3)

40536

Department of Neurology; University of Kentucky Medical Center, Lexington

66160

University of Kansas Medical Center - Landon Center on Aging, Kansas City

94115

California Pacific Medical Center, San Francisco